Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome:An Italian prospective multicenter study

作     者：Fabrizio Presicce Francesco Barrese Andrea Cantiani Alessio Filianoti Domenico Tuzzolo Paolo Di Palma Stefano Lauretti Stefano Brunori Marco Martini Fabrizio Presicce;Francesco Barrese;Andrea Cantiani;Alessio Filianoti;Domenico Tuzzolo;Paolo Di Palma;Stefano Lauretti;Stefano Brunori;Marco Martini

作者机构：San Filippo Neri HospitalDepartment of UrologyRomeItaly Sant’Eugenio HospitalDepartment of UrologyRomeItaly Casa del Sole ClinicDepartment of UrologyFormiaItaly Fabrizio Spaziani HospitalDepartment of UrologyFrosinoneItaly Santa Caterina della Rosa ClinicDepartment of UrologyRomeItaly Villa Stuart ClinicDepartment of UrologyRomeItaly 

出 版 物：《Asian Journal of Urology》 (亚洲泌尿外科杂志（英文）)

年 卷 期：2022年第9卷第2期

页      面：139-145页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

主　　题：Boswellia serrata Chronic prostatitis Chronic pelvic pain syndrome Propolis Treatment 

摘      要：Objective:To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome(CP/CPPS).Methods:Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months.Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index(NIH-CPSI),the International Prostate Symptom Scores(IPSS),International Index of Erectile Function(IIEF),four-glass test,uroflowmetry,and prostate-specific antigen assessments at baseline and at Week 4,and Week 12.Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score.Secondary outcomes included improvement of micturition and quality of life(QoL)domains of NIH-CPSI questionnaire.Results:A total of 61 males were enrolled.No adverse events were reported.Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score(mean difference:-9.2;p0.01),NIH-CPSI pain domain(mean difference:-5.5;p0.01),NIH-CPSI micturition domain,NIH-CPSI QoL domain,and IPSS total score(mean difference:-5.6;p0.01).No significant changes from baseline in terms of IIEF score or maximum flow rate were observed.At final follow-up(Day 90),further significant improvements in terms of NIH-CPSI total score(mean difference:-12.2;p0.01),NIH-CPSI pain domain(mean difference:-6.6;p0.01),NIH-CPSI micturition domain,NIH-CPSI QoL domain,and IPSS total score were reported.Conclusion:Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS.